BAR502 Combination Therapy for NAFLD Lipid Deposition Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are inadequate, necessitating the development of new treatments to address metabolic abnormalities, lipid accumulation in hepatocytes, and associated complications such as liver fibrosis and cirrhosis.
Innovation Solution
A pharmaceutical combination of 6α-ethyl-3α,7α-dihydroxy-24-nor-5β-cholan-23-ol (BAR502) with either a statin like atorvastatin or ursodesoxycholic acid (UDCA) is administered to treat NAFLD and NASH, reducing lipid deposition, insulin resistance, and hepatic damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no approved effective therapies are used for NAFLD and NASH, then current treatment options are insufficient, but developing new therapies requires identifying effective combinations that reduce lipid accumulation and hepatic damage
Solution Approach 1:
The patent combines BAR502 with statins or ursodesoxycholic acid to create a pharmaceutical composition that achieves superior therapeutic effect compared to individual treatments. This combination approach addresses the insufficiency of current single-agent therapies by merging mechanisms of action to simultaneously reduce lipid accumulation, inflammation, and hepatic damage.
Solution Approach 2:
The invention creates a composite therapeutic system by formulating BAR502 in combination with statins or ursodesoxycholic acid. This composite approach integrates multiple pharmacological agents with complementary mechanisms to achieve comprehensive treatment of NAFLD and NASH, overcoming the limitations of existing single-drug therapies.
2Reliability
If individual treatments are used, then treatment simplicity is maintained, but therapeutic effect is insufficient compared to combination therapy
Solution Approach 1:
The patent merges BAR502 with statins or ursodesoxycholic acid in a single pharmaceutical composition, achieving superior therapeutic effect while maintaining practical treatment simplicity. The combination is formulated as a ready-to-administer composition that reduces lipid accumulation and hepatic damage more effectively than individual agents.
3Object-affected harmful factors
If combination therapy with BAR502 and statin/UDCA is administered, then lipid deposition and hepatic damage are reduced, but treatment regimen complexity increases
Solution Approach 1:
The patent combines BAR502 with statins or ursodesoxycholic acid into a unified pharmaceutical composition that simultaneously addresses multiple pathogenic mechanisms. This merging of agents in a single formulation reduces hepatic damage and lipid deposition while consolidating the treatment regimen into one administered unit.
Data Source
AI summary
The present invention relates to a pharmaceutical combination comprising 6α-ethyl-3α, 7 a-dihydroxy-24-nor-5 β-cholan-23-ol or a pharmaceutically acceptable salt thereof and a statin and to a combination comprising 6α-ethyl-3α, 7α-dihydroxy-24-nor-5β-cholan-23-ol and ursodesoxycholic acid and the use thereof for the treatment of non-alcoholic liver steatosis and non-alcoholic steatohepatitis.